Research Topic: COVID-19

Sarocladium implicatum: an unusual agent of opportunistic infection in a COVID-19 patient

mycolabadmin

A 64-year-old man hospitalized with COVID-19 developed a serious fungal infection from Sarocladium implicatum, an unusual fungus rarely found in humans. The infection appeared in his bloodstream and lungs while his immune system was severely weakened by the virus and medications. Doctors identified the fungus using genetic testing and successfully treated him with voriconazole antifungal medication. This case highlights how COVID-19 patients in intensive care are vulnerable to rare opportunistic infections that require specialized laboratory testing to identify and treat.

Read More »

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

During the COVID-19 pandemic, some patients developed a severe fungal infection called mucormycosis alongside their coronavirus infection. This study found that 63 COVID-19 patients in Iran developed mucormycosis, which primarily affected the sinuses and brain. The researchers identified that a fungus called Rhizopus arrhizus caused most infections, and patients who received corticosteroids (used to treat severe COVID-19) had a higher risk, especially those who developed diabetes from the steroids.

Read More »

COVID-19-associated Pulmonary Aspergillosis in Mechanically Ventilated Patients at 7 US Hospitals: Epidemiology and Estimated Likelihood of Invasive Pulmonary Aspergillosis—Results of the Prospective MSG-017 Study

mycolabadmin

A fungal infection caused by Aspergillus commonly occurs in COVID-19 patients on ventilators, affecting about 7% of cases. The study found that having this infection was linked to high death rates, but it was unclear whether the fungal infection itself or the severe COVID-19 caused the deaths. Single positive test results for the fungus are not reliable for diagnosis, and antifungal drugs did not improve survival rates.

Read More »

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19, patients in intensive care sometimes develop dangerous fungal infections. Doctors use a blood test to measure a fungal marker called BDG to help diagnose these infections. This study found that even without confirmed fungal infection, high BDG levels predicted who would not survive, but giving antifungal medications improved survival even without proven infection.

Read More »

One for All and All for One: Multikingdom Interplay in Severe Viral Pneumonia

mycolabadmin

This editorial discusses how bacteria, viruses, and fungi interact in the lungs during severe pneumonia from COVID-19 or influenza. When mechanically ventilated patients with COVID-19 had bacterial infections detected, their immune systems released more inflammatory chemicals. However, the same pattern was not observed in influenza patients. Understanding how all these microorganisms work together may help doctors better treat these serious lung infections.

Read More »

Acute Respiratory Distress Syndrome Due to COVID-19-Associated Pulmonary Aspergillosis with Rare Extensive Tracheobronchial Pseudomembranous Involvement: A Case Report

mycolabadmin

An elderly COVID-19 patient developed a rare and severe fungal infection caused by Aspergillus fungus in the airways, creating yellowish-white membrane-like deposits that blocked breathing. Despite identification of the fungus through examination and modern genetic testing, and treatment with antifungal medications, the patient’s condition worsened rapidly leading to organ failure and death. This case highlights how fungal infections can complicate COVID-19, especially in elderly patients on multiple medications, and stresses the importance of early recognition and immediate antifungal treatment.

Read More »

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

This study found that COVID-19 patients in northwestern Iran who received high-dose steroid treatment developed serious fungal infections called mucormycosis. The infection was caused primarily by a fungus called Rhizopus arrhizus and affected mainly the sinuses and brain. The steroids used to treat COVID-19 weakened patients’ immune systems and triggered diabetes, both of which made them vulnerable to this dangerous fungal infection.

Read More »
Scroll to Top